Elizabeth Barba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elizabeth Barba has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
- Fernando Azpiroz
Digestive System Research Unit, University Hospital Vall d'Hebron, 08035 Barcelona, Spain; Departament de Medicina, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Spain
15 shared publications Anna Accarino
Digestive System Research Unit, University Hospital Vall d'Hebron, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
8 shared publications- Alberto Ezquerra-Durán
Neurogastroenterology and Motility Unit, Gastroenterology Department, Institut Clínic de Malalties Digestives i Metabòliques (ICMDM), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
7 shared publications - Luis Gerardo Alcala-Gonzalez
Digestive System Research Unit, Department of Digestive Diseases Vall d'Hebron University Hospital Barcelona Spain
6 shared publications - Carolina Malagelada
Digestive System Research Unit, University Hospital Vall d’Hebron, 08035 Barcelona, Spain
5 shared publications Emanuel Burri
Digestive System Research Unit University Hospital Vall d'Hebron; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd); Universitat Autònoma de Barcelona Bellaterra Spain
5 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by Instituto Mexicano del Seguro Social in Clínicas de gastroenterología de México (English Edition)
- Vol. 2 (2)
Usefulness of diagnostic tests in constipation
Introduction The diagnostic approach to constipation must be selective, targeted, and stepwise, avoiding both the underutilization and the indiscriminate use of tests. Diagnostic investigations are not intended to “confirm” constipation, but rather to identify its underlying mechanism, differentiate pathophysiological subtypes, and guide specific therapeutic decisions. In patients with persistent constipation despite initial measures, functional evaluation […]
- 2 September 2026
- Published by Instituto Mexicano del Seguro Social in Clínicas de gastroenterología de México (English Edition)
- Vol. 2 (2)
Open AccessUsefulness of diagnostic tests in constipation
Introduction The diagnostic approach to constipation must be selective, targeted, and stepwise, avoiding both the underutilization and the indiscriminate use of tests. Diagnostic investigations are not intended to “confirm” constipation, but rather to identify its underlying mechanism, differentiate pathophysiological subtypes, and guide specific therapeutic decisions. In patients with persistent constipation despite initial measures, functional evaluation […]
- Open Access
- 25 June 2026
- Published by Instituto Mexicano del Seguro Social in Clínicas de gastroenterología de México
- Vol. 2 (2)
Utilidad de las pruebas diagnósticas en el estreñimiento
El contenido completo estará disponible en breve. ¡Gracias por tu paciencia!
- 25 June 2026
- Published by Instituto Mexicano del Seguro Social in Clínicas de gastroenterología de México
- Vol. 2 (2)
Open AccessUtilidad de las pruebas diagnósticas en el estreñimiento
El contenido completo estará disponible en breve. ¡Gracias por tu paciencia!
- Open Access
- 13 February 2026
- Published by Elsevier in Gastroenterology
- Vol. 171 (1) , 161-163
Biofeedback Guided by Thoracoabdominal Wall Motion for the Treatment of Rumination: A Randomized Placebo-Controlled Trial
- 13 February 2026
- Published by Elsevier in Gastroenterology
- Vol. 171 (1) , 161-163
Open AccessBiofeedback Guided by Thoracoabdominal Wall Motion for the Treatment of Rumination: A Randomized Placebo-Controlled Trial
- 19 January 2026
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 38 (1) , e70248
Clinical Application of the London Classification in 3D High‐Definition Anorectal Manometry: Prevalence, Limitations, and Complementary Metrics
Background: The London classification (LC) standardizes the interpretation of anorectal manometry, but real‐world data using high‐definition three‐dimensional anorectal manometry (3D HD‐ARM) remain limited. Objective: To characterize anorectal manometric patterns in a large 3D HD‐ARM cohort applying the LC and to assess additional functional parameters not included in the classification. Methods: We retrospectively analyzed 300 consecutive 3D HD‐ARM studies with balloon expulsion testing (BET). Clinical subgroups were defined using validated questionnaires: St. Mark's score for anal incontinence (AI) and Knowles‐Eccersley‐Scott Symptom score for chronic constipation (CC). Results: Anal incontinence (AI) was highly prevalent (81.7%), with 75.7% reporting moderate‐to‐severe fecal incontinence. CC was present in 56.7%, and 49.1% showed overlapping symptoms. The most frequent major finding was rectal hyposensitivity (43.3%) and anal normotension with hypocontractility (16.3%). Anal normotension with hypocontractility best correlated with AI [OR 14.5 (95% CI 1.9–110.2; p = 0.010)], while anal hypertension was more frequent in CC [OR 2.2 (95% CI 1.3–3.9; p = 0.005)]. Rectoanal coordination disorders were common, with inconclusive patterns in 54.4%, limiting diagnostic precision. Among constipated patients with obstructive defecation syndrome (ODS), pathological coordination was more frequent [OR 3.5 (95% CI 1.1–12.1; p = 0.040)]. Additional parameters not included in the LC—reduced functional anal canal length and shorter sustained squeeze duration—were more evident in women with AI, whereas ultraslow waves were associated with CC. Sphincter defects were detected in 13%, mainly in women and AI patients. Conclusion: The LC enables consistent phenotyping of anorectal dysfunction, highlighting major abnormalities as highly prevalent. However, frequent minor and inconclusive findings—particularly in defecatory coordination—underscore limitations of the current classification and the need for refinement.
- 19 January 2026
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 38 (1) , e70248
Clinical Application of the London Classification in 3D High‐Definition Anorectal Manometry: Prevalence, Limitations, and Complementary Metrics
Background: The London classification (LC) standardizes the interpretation of anorectal manometry, but real‐world data using high‐definition three‐dimensional anorectal manometry (3D HD‐ARM) remain limited. Objective: To characterize anorectal manometric patterns in a large 3D HD‐ARM cohort applying the LC and to assess additional functional parameters not included in the classification. Methods: We retrospectively analyzed 300 consecutive 3D HD‐ARM studies with balloon expulsion testing (BET). Clinical subgroups were defined using validated questionnaires: St. Mark's score for anal incontinence (AI) and Knowles‐Eccersley‐Scott Symptom score for chronic constipation (CC). Results: Anal incontinence (AI) was highly prevalent (81.7%), with 75.7% reporting moderate‐to‐severe fecal incontinence. CC was present in 56.7%, and 49.1% showed overlapping symptoms. The most frequent major finding was rectal hyposensitivity (43.3%) and anal normotension with hypocontractility (16.3%). Anal normotension with hypocontractility best correlated with AI [OR 14.5 (95% CI 1.9–110.2; p = 0.010)], while anal hypertension was more frequent in CC [OR 2.2 (95% CI 1.3–3.9; p = 0.005)]. Rectoanal coordination disorders were common, with inconclusive patterns in 54.4%, limiting diagnostic precision. Among constipated patients with obstructive defecation syndrome (ODS), pathological coordination was more frequent [OR 3.5 (95% CI 1.1–12.1; p = 0.040)]. Additional parameters not included in the LC—reduced functional anal canal length and shorter sustained squeeze duration—were more evident in women with AI, whereas ultraslow waves were associated with CC. Sphincter defects were detected in 13%, mainly in women and AI patients. Conclusion: The LC enables consistent phenotyping of anorectal dysfunction, highlighting major abnormalities as highly prevalent. However, frequent minor and inconclusive findings—particularly in defecatory coordination—underscore limitations of the current classification and the need for refinement.
- Open Access
- 22 August 2025
- Published by Wiley in United European Gastroenterology Journal
- Vol. 13 (9) , 1613-1651
European Consensus on Functional Bloating and Abdominal Distension—An ESNM/UEG Recommendations for Clinical Management
Introduction: Abdominal distension is an objective visible sign of increased abdominal girth. Bloating is a feeling of abdominal fullness and discomfort. Bloating may be associated or not with abdominal distension. Bloating and abdominal distension are among the most commonly reported gastrointestinal symptoms and may be associated with both organic and functional disorders. Nevertheless, specific consensus and recommendations on diagnosis, underlying mechanisms, assessment and management of functional bloating and abdominal distension are still lacking. The aim of this European consensus, then, is to provide expert opinions and recommendations on the epidemiology, diagnosis, pathophysiology and treatment of functional bloating and abdominal distension. Methods: A multidisciplinary team of experts in the field, including European specialists and national societies, participated in the development of this consensus. Relevant questions were formulated and addressed through a literature review and statements were developed and voted using a Delphi process. Results: Functional bloating and abdominal distension are common and frequently overlap with other disorders of gut‐brain interaction. Diagnosis is made according to the Rome IV criteria after the exclusion of organic disease, based on the physical examination and assessment of the patient's medical history and alarming signs. In the absence of alarming signs or any relevant finding, clinical laboratory, imaging or endoscopic tests are unnecessary. The pathophysiology of functional bloating and abdominal distension is multifactorial and involves visceral hypersensitivity, abdomino‐phrenic dyssynergia, intestinal dysmotility and dysbiosis. Treatment may include dietary modifications (e.g. lactose‐limiting diet and low FODMAP diet), probiotics, antispasmodics (e.g., otilonium bromide, peppermint oil), rifaximin, secretagogues (e.g., linaclotide), neuromodulators (e.g., serotonin‐norepinephrine reuptake inhibitors, tricyclic antidepressants, buspirone), and plethysmography‐based biofeedback. Moreover, cognitive behaviour therapy and hypnotherapy can be used in case of functional bloating associated with irritable bowel syndrome. Conclusion: This consensus provides an evidence‐based framework for the evaluation and treatment of patients with functional bloating and abdominal distension.
- 22 August 2025
- Published by Wiley in United European Gastroenterology Journal
- Vol. 13 (9) , 1613-1651
Open AccessEuropean Consensus on Functional Bloating and Abdominal Distension—An ESNM/UEG Recommendations for Clinical Management
Introduction: Abdominal distension is an objective visible sign of increased abdominal girth. Bloating is a feeling of abdominal fullness and discomfort. Bloating may be associated or not with abdominal distension. Bloating and abdominal distension are among the most commonly reported gastrointestinal symptoms and may be associated with both organic and functional disorders. Nevertheless, specific consensus and recommendations on diagnosis, underlying mechanisms, assessment and management of functional bloating and abdominal distension are still lacking. The aim of this European consensus, then, is to provide expert opinions and recommendations on the epidemiology, diagnosis, pathophysiology and treatment of functional bloating and abdominal distension. Methods: A multidisciplinary team of experts in the field, including European specialists and national societies, participated in the development of this consensus. Relevant questions were formulated and addressed through a literature review and statements were developed and voted using a Delphi process. Results: Functional bloating and abdominal distension are common and frequently overlap with other disorders of gut‐brain interaction. Diagnosis is made according to the Rome IV criteria after the exclusion of organic disease, based on the physical examination and assessment of the patient's medical history and alarming signs. In the absence of alarming signs or any relevant finding, clinical laboratory, imaging or endoscopic tests are unnecessary. The pathophysiology of functional bloating and abdominal distension is multifactorial and involves visceral hypersensitivity, abdomino‐phrenic dyssynergia, intestinal dysmotility and dysbiosis. Treatment may include dietary modifications (e.g. lactose‐limiting diet and low FODMAP diet), probiotics, antispasmodics (e.g., otilonium bromide, peppermint oil), rifaximin, secretagogues (e.g., linaclotide), neuromodulators (e.g., serotonin‐norepinephrine reuptake inhibitors, tricyclic antidepressants, buspirone), and plethysmography‐based biofeedback. Moreover, cognitive behaviour therapy and hypnotherapy can be used in case of functional bloating associated with irritable bowel syndrome. Conclusion: This consensus provides an evidence‐based framework for the evaluation and treatment of patients with functional bloating and abdominal distension.
- 2 June 2025
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 37 (12) , e70090
Diagnostic Accuracy and Inter‐Rater Reliability of Three‐Dimensional High Resolution Anorectal Manometry (3D‐HR‐ARM) in the Diagnosis of Obstetric Anal Sphincter Injuries (OASIs): A Feasibility Study
Background: Obstetric anal sphincter injuries (OASIs) occur during childbirth, affecting up to 11.0% of women. Three‐Dimensional High‐Resolution Anorectal Manometry (3D‐HR‐ARM) provides an advanced evaluation of pathophysiological anorectal abnormalities and allows identification of potential lesions. The aim of the study was to evaluate the diagnostic accuracy and inter‐rater reliability of (3D‐HR‐ARM) in identifying OASIs compared to ultrasound assessment. Methods: A retrospective cohort study was conducted at a tertiary referral center from January 2021 to June 2023. Women with anal incontinence (AI) following a vaginal delivery underwent assessment with both 3D‐HR‐ARM and endoanal ultrasound (3D‐EAUS). Diagnostic accuracy in identifying anal sphincter defects was determined using 3D‐EAUS as the gold standard, and inter‐rater reliability was assessed among multiple observers. Key Results: Among 35 women, 19 had OASIs. For identifying severe residual defects (global Starck score ≥ 8), 3D‐HR‐ARM demonstrated an accuracy of 95.7% (95% CI 79.0–99.2), sensitivity of 100% (95% CI 64.6–100), specificity of 93.8% (95% CI 71.7–98.9), positive predictive value (PPV) of 87.5% (95% CI 52.9–97.8), and negative predictive value of 100% (95% CI 79.6–100). However, its accuracy decreased to 68.6% (95% CI 52.0–81.4) for detecting any sphincter defect. Inter‐rater agreement varied from good ( κ = 0.60) to mild ( κ = 0.27), depending on the observer pair. Conclusions: 3D‐HR‐ARM shows potential for the identification of severe OASIs in women with AI symptoms. However, its moderate accuracy for mild defects and significant inter‐rater variability underscore the need for standardized protocols and additional training to improve reliability.
- 2 June 2025
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 37 (12) , e70090
Diagnostic Accuracy and Inter‐Rater Reliability of Three‐Dimensional High Resolution Anorectal Manometry (3D‐HR‐ARM) in the Diagnosis of Obstetric Anal Sphincter Injuries (OASIs): A Feasibility Study
Background: Obstetric anal sphincter injuries (OASIs) occur during childbirth, affecting up to 11.0% of women. Three‐Dimensional High‐Resolution Anorectal Manometry (3D‐HR‐ARM) provides an advanced evaluation of pathophysiological anorectal abnormalities and allows identification of potential lesions. The aim of the study was to evaluate the diagnostic accuracy and inter‐rater reliability of (3D‐HR‐ARM) in identifying OASIs compared to ultrasound assessment. Methods: A retrospective cohort study was conducted at a tertiary referral center from January 2021 to June 2023. Women with anal incontinence (AI) following a vaginal delivery underwent assessment with both 3D‐HR‐ARM and endoanal ultrasound (3D‐EAUS). Diagnostic accuracy in identifying anal sphincter defects was determined using 3D‐EAUS as the gold standard, and inter‐rater reliability was assessed among multiple observers. Key Results: Among 35 women, 19 had OASIs. For identifying severe residual defects (global Starck score ≥ 8), 3D‐HR‐ARM demonstrated an accuracy of 95.7% (95% CI 79.0–99.2), sensitivity of 100% (95% CI 64.6–100), specificity of 93.8% (95% CI 71.7–98.9), positive predictive value (PPV) of 87.5% (95% CI 52.9–97.8), and negative predictive value of 100% (95% CI 79.6–100). However, its accuracy decreased to 68.6% (95% CI 52.0–81.4) for detecting any sphincter defect. Inter‐rater agreement varied from good ( κ = 0.60) to mild ( κ = 0.27), depending on the observer pair. Conclusions: 3D‐HR‐ARM shows potential for the identification of severe OASIs in women with AI symptoms. However, its moderate accuracy for mild defects and significant inter‐rater variability underscore the need for standardized protocols and additional training to improve reliability.
- 6 May 2025
- Published by Wiley in Neurogastroenterology & Motility
- p. e70072
Practical Validation of the COuGH RefluX Score: A Multicenter Study in Patients From Hispano‐America
Background: Laryngopharyngeal reflux symptoms (LPS) are often attributed to gastroesophageal reflux disease (GERD), yet objective testing confirms GERD in only a small subset of patients. The COuGH RefluX score, previously validated in North American and Taiwanese populations, offers a non‐invasive method to stratify GERD likelihood in patients with LPS. This study aimed to evaluate its performance in a real‐world Hispano‐American cohort.Methods: We performed a multicenter, retrospective cohort study in 459 adult patients from seven Neurogastroenterology units in Spain and Latin America, referred for LPS between 2018 and 2024. All patients underwent endoscopy, high‐resolution esophageal manometry, and 24‐h pH or Ph‐impedance monitoring. Two versions of the COuGH RefluX score—original (including endoscopy and manometry data) and practical (including only endoscopy data)—were calculated. GERD status was defined per Lyon 2.0 criteria.Key Results: Proven GERD was identified in 164 patients (36%). The original COuGH RefluX score showed an AUC of 0.706, with 89% sensitivity and 89% specificity. The practical version showed an AUC of 0.684, maintaining the same sensitivity and specificity (both 89%). Compared to the original COuGH RefluX score, the practical version misclassified 54 patients due to undetected hiatal hernia on endoscopy alone; among these, 15 patients initially classified as indeterminate were downgraded to low likelihood—4 with proven GERD and 11 with unproven GERD. A subset of 197 (43%) patients reported at least three cough episodes during reflux monitoring. Among those with strong symptom association (n = 18), 67% had a high COuGH RefluX score, suggestive of a high GERD likelihood.Conclusions: The COuGH RefluX score effectively stratifies GERD probability in patients with LPS. It may also identify patients with significant symptom‐reflux associations, guiding targeted testing and therapy. This pragmatic tool could improve resource allocation by reducing unnecessary invasive testing in low‐risk patients.
- 6 May 2025
- Published by Wiley in Neurogastroenterology & Motility
- p. e70072
Practical Validation of the COuGH RefluX Score: A Multicenter Study in Patients From Hispano‐America
Background: Laryngopharyngeal reflux symptoms (LPS) are often attributed to gastroesophageal reflux disease (GERD), yet objective testing confirms GERD in only a small subset of patients. The COuGH RefluX score, previously validated in North American and Taiwanese populations, offers a non‐invasive method to stratify GERD likelihood in patients with LPS. This study aimed to evaluate its performance in a real‐world Hispano‐American cohort.Methods: We performed a multicenter, retrospective cohort study in 459 adult patients from seven Neurogastroenterology units in Spain and Latin America, referred for LPS between 2018 and 2024. All patients underwent endoscopy, high‐resolution esophageal manometry, and 24‐h pH or Ph‐impedance monitoring. Two versions of the COuGH RefluX score—original (including endoscopy and manometry data) and practical (including only endoscopy data)—were calculated. GERD status was defined per Lyon 2.0 criteria.Key Results: Proven GERD was identified in 164 patients (36%). The original COuGH RefluX score showed an AUC of 0.706, with 89% sensitivity and 89% specificity. The practical version showed an AUC of 0.684, maintaining the same sensitivity and specificity (both 89%). Compared to the original COuGH RefluX score, the practical version misclassified 54 patients due to undetected hiatal hernia on endoscopy alone; among these, 15 patients initially classified as indeterminate were downgraded to low likelihood—4 with proven GERD and 11 with unproven GERD. A subset of 197 (43%) patients reported at least three cough episodes during reflux monitoring. Among those with strong symptom association (n = 18), 67% had a high COuGH RefluX score, suggestive of a high GERD likelihood.Conclusions: The COuGH RefluX score effectively stratifies GERD probability in patients with LPS. It may also identify patients with significant symptom‐reflux associations, guiding targeted testing and therapy. This pragmatic tool could improve resource allocation by reducing unnecessary invasive testing in low‐risk patients.
- 3 April 2025
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 37 (9) , e70041
Diaphragmatic Flutter Disease: Key Findings in Esophageal Manometry and Biofeedback Treatment
Background: Diaphragmatic flutter (DF) is a rare condition characterized by involuntary contractions of the diaphragmatic muscle, often accompanied by accessory respiratory muscle contractions. Symptoms can include epigastric pulsations, abdominal pain, and reflux. Diagnosis is challenging, and treatment is based on individual cases. This study presents the first case series of DF assessed using high‐resolution esophageal manometry (HREM), electromyography (EMG), and plethysmography belts, and the symptomatic improvement through biofeedback therapy.Methods: This case series includes patients with refractory abdominal spasms referred to the digestive motility department from 2018 to 2024.Results: Two patients were diagnosed with DF using HREM, which reveals a characteristic pattern of oscillating increases in intragastric pressure, repetitive crural diaphragm spasms, and pharyngeal contraction during abdominal spasms. Symptomatic control was achieved following abdomino‐thoracic biofeedback (ATB) therapy by plethysmography belts.Conclusions: High‐resolution esophageal manometry offers a reliable, non‐invasive method for diagnosis of DF, presenting a specific manometric pattern. ATB appears to be an effective treatment for DF, suggesting that voluntary but unconsciously initiated movement disorders may contribute to the condition.
- 3 April 2025
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 37 (9) , e70041
Diaphragmatic Flutter Disease: Key Findings in Esophageal Manometry and Biofeedback Treatment
Background: Diaphragmatic flutter (DF) is a rare condition characterized by involuntary contractions of the diaphragmatic muscle, often accompanied by accessory respiratory muscle contractions. Symptoms can include epigastric pulsations, abdominal pain, and reflux. Diagnosis is challenging, and treatment is based on individual cases. This study presents the first case series of DF assessed using high‐resolution esophageal manometry (HREM), electromyography (EMG), and plethysmography belts, and the symptomatic improvement through biofeedback therapy.Methods: This case series includes patients with refractory abdominal spasms referred to the digestive motility department from 2018 to 2024.Results: Two patients were diagnosed with DF using HREM, which reveals a characteristic pattern of oscillating increases in intragastric pressure, repetitive crural diaphragm spasms, and pharyngeal contraction during abdominal spasms. Symptomatic control was achieved following abdomino‐thoracic biofeedback (ATB) therapy by plethysmography belts.Conclusions: High‐resolution esophageal manometry offers a reliable, non‐invasive method for diagnosis of DF, presenting a specific manometric pattern. ATB appears to be an effective treatment for DF, suggesting that voluntary but unconsciously initiated movement disorders may contribute to the condition.
- 5 February 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (6) , 3266-3279
The role of prokinetics in managing gastrointestinal involvement in SSc: a systematic literature review
Objectives: Gastrointestinal involvement (GI) in SSc is frequent and heterogeneous, manifesting with different degrees of dysmotility. This systematic literature review aimed to summarize evidence on prokinetics for treating SSc-related GI dysmotility. Methods: Studies investigating the effects of prokinetic agents on GI function and/or GI symptoms in patients with SSc were systematically identified on PubMed and Embase. A qualitative data synthesis was conducted, given the (anticipated) wide heterogeneity in study designs, interventions and outcomes. Results: Twenty-one studies evaluating the effects of prokinetics in patients with SSc were included. Thirteen studies focused on GI motility using objective tests, eight assessed clinical responses, and six evaluated both. Cisapride (n = 5 studies), metoclopramide (n = 7 studies), octreotide (n = 4 studies) and prucalopride (n = 1 study) were among the most studied prokinetics, with varying effects on different GI anatomical regions. While metoclopramide consistently improved overall GI motility, other prokinetics provided selective benefits; cisapride improved gastric emptying and colonic motility, but not oesophageal motility, and octreotide improved small bowel motility but delayed gastric emptying. Regarding symptomatic improvement, only prucalopride was evaluated using a validated patient questionnaire, showing improvement in both upper and lower GI symptoms. Conclusion: Prokinetic drugs may improve GI motility and symptoms in patients with SSc. There is an unmet need for future well-designed studies to refine patient stratification and optimize treatment outcomes.
- 5 February 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (6) , 3266-3279
The role of prokinetics in managing gastrointestinal involvement in SSc: a systematic literature review
Objectives: Gastrointestinal involvement (GI) in SSc is frequent and heterogeneous, manifesting with different degrees of dysmotility. This systematic literature review aimed to summarize evidence on prokinetics for treating SSc-related GI dysmotility. Methods: Studies investigating the effects of prokinetic agents on GI function and/or GI symptoms in patients with SSc were systematically identified on PubMed and Embase. A qualitative data synthesis was conducted, given the (anticipated) wide heterogeneity in study designs, interventions and outcomes. Results: Twenty-one studies evaluating the effects of prokinetics in patients with SSc were included. Thirteen studies focused on GI motility using objective tests, eight assessed clinical responses, and six evaluated both. Cisapride (n = 5 studies), metoclopramide (n = 7 studies), octreotide (n = 4 studies) and prucalopride (n = 1 study) were among the most studied prokinetics, with varying effects on different GI anatomical regions. While metoclopramide consistently improved overall GI motility, other prokinetics provided selective benefits; cisapride improved gastric emptying and colonic motility, but not oesophageal motility, and octreotide improved small bowel motility but delayed gastric emptying. Regarding symptomatic improvement, only prucalopride was evaluated using a validated patient questionnaire, showing improvement in both upper and lower GI symptoms. Conclusion: Prokinetic drugs may improve GI motility and symptoms in patients with SSc. There is an unmet need for future well-designed studies to refine patient stratification and optimize treatment outcomes.